Hand, Foot And Mouth Disease - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Hand, Foot And Mouth Disease - Pipeline Review, H1 2016', provides an overview of the Hand, Foot And Mouth Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hand, Foot And Mouth Disease , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hand, Foot And Mouth Disease and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Hand, Foot And Mouth Disease - The report reviews pipeline therapeutics for Hand, Foot And Mouth Disease by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Hand, Foot And Mouth Disease therapeutics and enlists all their major and minor projects - The report assesses Hand, Foot And Mouth Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Hand, Foot And Mouth Disease Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Hand, Foot And Mouth Disease - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Hand, Foot And Mouth Disease pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Hand, Foot And Mouth Disease Overview 6 Therapeutics Development 7 Pipeline Products for Hand, Foot And Mouth Disease - Overview 7 Pipeline Products for Hand, Foot And Mouth Disease - Comparative Analysis 8 Hand, Foot And Mouth Disease - Therapeutics under Development by Companies 9 Hand, Foot And Mouth Disease - Therapeutics under Investigation by Universities/Institutes 10 Hand, Foot And Mouth Disease - Pipeline Products Glance 11 Clinical Stage Products 11 Early Stage Products 12 Hand, Foot And Mouth Disease - Products under Development by Companies 13 Hand, Foot And Mouth Disease - Products under Investigation by Universities/Institutes 14 Hand, Foot And Mouth Disease - Companies Involved in Therapeutics Development 15 CJ HealthCare Corp. 15 Sentinext Therapeutics Sdn Bhd 16 Takeda Pharmaceutical Company Limited 17 Hand, Foot And Mouth Disease - Therapeutics Assessment 18 Assessment by Monotherapy Products 18 Assessment by Combination Products 19 Assessment by Route of Administration 20 Assessment by Molecule Type 21 Drug Profiles 23 (coxsackievirus [serotype A16] + Enterovirus [serotype 71]) vaccine - Drug Profile 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 CJ-40010 - Drug Profile 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 D-5 - Drug Profile 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Enterovirus [serotype EV-A71] (virus like particle, bivalent) vaccine - Drug Profile 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 hand, foot and mouth disease (viral like particle, bivalent) vaccine - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 TAK-021 - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Hand, Foot And Mouth Disease - Recent Pipeline Updates 29 Hand, Foot And Mouth Disease - Dormant Projects 30 Hand, Foot And Mouth Disease - Product Development Milestones 31 Featured News & Press Releases 31 Mar 11, 2012: Inviragen Reports Top-Line Results From Phase I Trial Of INV21 Vaccine For Treatment Of Hand, Foot And Mouth Disease 31 Appendix 32 Methodology 32 Coverage 32 Secondary Research 32 Primary Research 32 Expert Panel Validation 32 Contact Us 32 Disclaimer 33
List of Tables
Number of Products under Development for Hand, Foot And Mouth Disease, H1 2016 7 Number of Products under Development for Hand, Foot And Mouth Disease - Comparative Analysis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Number of Products under Investigation by Universities/Institutes, H1 2016 10 Comparative Analysis by Clinical Stage Development, H1 2016 11 Comparative Analysis by Early Stage Development, H1 2016 12 Products under Development by Companies, H1 2016 13 Products under Investigation by Universities/Institutes, H1 2016 14 Hand, Foot And Mouth Disease - Pipeline by CJ HealthCare Corp., H1 2016 15 Hand, Foot And Mouth Disease - Pipeline by Sentinext Therapeutics Sdn Bhd, H1 2016 16 Hand, Foot And Mouth Disease - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 17 Assessment by Monotherapy Products, H1 2016 18 Assessment by Combination Products, H1 2016 19 Number of Products by Stage and Route of Administration, H1 2016 20 Number of Products by Stage and Molecule Type, H1 2016 22 Hand, Foot And Mouth Disease Therapeutics - Recent Pipeline Updates, H1 2016 29 Hand, Foot And Mouth Disease - Dormant Projects, H1 2016 30
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.